HPTN
Dec 3, 2020 | In the Media, News
Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, was featured in a Nov 30 article by Global News Wire which announced that ICAP has been awarded a seven-year grant from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the...
Jul 7, 2020 | News
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...
May 19, 2020 | In the Media, News
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC)...
Jul 22, 2019 | In the Media, News
HPTN 071 (PopART) examined the impact of a package of HIV prevention interventions, including universal testing and treatment, on community-level HIV incidence amongst more than one million people living in 21 urban and peri-urban communities in Zambia and South...
Jul 11, 2019 | News
ICAP at Columbia University is playing a key role in testing the feasibility of a potential breakthrough in the global effort to stop HIV transmission. The Harlem Prevention Center, one of ICAP’s two clinical research centers in New York, is participating in a...
